Research: All Articles
COVID’s Impact On The Flow Of Counterfeits
What have we learned about counterfeit medicines during the pandemic? And what does it mean for proposals to import the drug supplies of other countries like Canada?
[...]O’Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J. Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls — United States, 2019–2020. MMWR Morb Mortal Wkly Rep. ePub: 14 December 2021.
Summary What is already known about this topic? Synthetic opioids, including illicitly manufactured fentanyls (IMFs), were involved in 64% of >100,000 estimated U.S. drug overdose deaths during May 2020–April 2021. What is added by this report? During 2019–2020, IMF-involved overdose deaths increased sharply in midwestern, southern, and western jurisdictions. During 2020, approximately 40% of IMF-involved…
[...]Conti R, Dusetzina S. B. , and Sachs R. “How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts.” Health Affairs. VOL. 39, NO. 3 (March 2020)
Abstract The Affordable Care Act contained a range of provisions that altered prescription drug access and affordability for patients, payers, and providers. Yet the act stopped short of instituting systemic changes in the pricing of drugs, in part to address concerns that more fundamental changes might disrupt the development of new medicines. Looking back a…
[...]Pitts, Peter J. “The Spreading Cancer of Counterfeit Drugs, Pharmaceutical Fakery Metastasizes from Lifestyle to Lifesaving Medicines,” Journal of Commercial Biotechnology (2020) 25(3), 20–14. doi: 10.5912/jcb940
INTRODUCTION Just as the coronavirus mutates to survive and thrive, so to do the purveyors of counterfeit medicines – with their high-speed “host” being the digi-tization of patient care. The future is now. So, how do we balance moving forward with user-friendly digitization, telemedicine and virtual healthcare delivery while simultaneously recognizing the unintended consequences of…
[...]Acri K (2020) State Pharmaceutical Importation Programmes: an Analysis of the Cost‐Effectiveness
This research paper (available here in pdf form), which was published in Journal of Pharmaceutical Health Services Research in March 2020. State Pharmaceutical Importation Programmes: an Analysis of the Cost‐Effectiveness Author: Dr. Kristina M.L. Acri née Lybecker, Senior Fellow at the Fraser Institute and Associate Professor of Economics at Colorado College in Colorado Springs Abstract: This…
[...]Research Study Confirms That Cheap And Safe Drug Importation Is Not Feasible
Research Study Confirms That Cheap And Safe Drug Importation Is Not Feasible Read the abstract for Dr. Acri’s article. In March 2020, the Journal of Pharmaceutical Health Services Research, an official journal of the Royal Pharmaceutical Society, published a study by Dr. Kristina M.L. Acri née Lybecker titled “State Pharmaceutical Importation Programmes: An Analysis of…
[...]Shepherd M (2019) New pathways for U.S. importation threaten Canadian prescription drug supply. Canadian Health Policy Journal,
This research paper is an update to The Effect Of U.S. Pharmaceutical Drug Importation On The Canadian Pharmaceutical Supply, published in 2010.
[...]Acri née Lybecker, Kristina M.L., State Pharmaceutical Importation Programs: An Analysis of the Cost Effectiveness (June 12, 2019). Colorado College Working Paper 2019-02 June 2019.
Abstract Recently proposed legislation in Colorado, Connecticut, Florida, Maine, Missouri, Oklahoma, Oregon, Utah, Vermont and West Virginia aims to reduce spending on pharmaceuticals by importing them from Canada. To examine the cost effectiveness of importation, this study analyzes 24 drugs from an online Canadian supplier, accounting for the cost savings, the cost of testing, the…
[...]Nayyar GM., Breman JG, Et Al. Falsified and Substandard Drugs: Stopping the Pandemic AJTMhH 2019 Mar; 18-0981.
Abstract Falsified and substandard medicines are associated with tens of thousands of deaths, mainly in young children in poor countries. Poor-quality drugs exact an annual economic toll of up to US$200 billion and contribute to the increasing peril of antimicrobial resistance. The WHO has emerged recently as the global leader in the battle against poor-quality…
[...]Former FBI Director Louis Freeh Updates His 2017 Report on the Threat of Congressional Drug Importation Proposals
Former FBI Director Louis Freeh has released an addendum to his 2017 Report on the Potential Impact of Drug Importation Proposals on U.S. Law Enforcement, concluding:
…the government has not done enough to evaluate and improve the capacity of law enforcement to deal with a new pipeline of drugs into the U.S. drug supply, all while . . . more illegal drugs are being shipped to the United States. Passing any drug importation scheme would erase the little progress we have made and set law enforcement further back on their heels.
[...]